These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17706797)

  • 21. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
    Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
    Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatinum ototoxicity in children, long-term follow up.
    Al-Khatib T; Cohen N; Carret AS; Daniel S
    Int J Pediatr Otorhinolaryngol; 2010 Aug; 74(8):913-9. PubMed ID: 20846503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions.
    Ozturan O; Jerger J; Lew H; Lynch GR
    Auris Nasus Larynx; 1996; 23():147-51. PubMed ID: 8809338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
    Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study.
    Littman TA; Magruder A; Strother DR
    J Am Acad Audiol; 1998 Aug; 9(4):257-62. PubMed ID: 9733234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of hearing in children with solid tumors treated by chemotherapy].
    Gryczyńska D; Rychwalska M; Pekacka K; Krawczyński M; Bodalski J
    Otolaryngol Pol; 2001; 55(2):179-83. PubMed ID: 11494735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
    Waissbluth S; Del Valle Á; Chuang A; Becker A
    Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.
    Gupta AA; Capra M; Papaioannou V; Hall G; Maze R; Dix D; Weitzman S
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):91-4. PubMed ID: 16462581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes to spontaneous otoacoustic emissions (SOAEs) due to cisplatin administration.
    Kuroda T; Chida E; Kashiwamura M; Matsumura M; Fukuda S
    Int J Audiol; 2008 Nov; 47(11):695-701. PubMed ID: 19031228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
    Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
    Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cisplatin ototoxicity. A clinical study].
    Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
    Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity.
    Wallach PM; Love SR; Fiorica JV; Hoffman MS; Flannery MT
    J Fla Med Assoc; 1992 Dec; 79(12):821-2. PubMed ID: 1474367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
    Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
    Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen.
    Arora R; Thakur JS; Azad RK; Mohindroo NK; Sharma DR; Seam RK
    Indian J Cancer; 2009; 46(4):311-7. PubMed ID: 19749461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ototoxicity from cisplatin therapy in childhood cancer.
    Coradini PP; Cigana L; Selistre SG; Rosito LS; Brunetto AL
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):355-60. PubMed ID: 17551394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity.
    Waissbluth S; Daniel SJ
    Hear Res; 2013 May; 299():37-45. PubMed ID: 23467171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
    Stöhr W; Langer T; Kremers A; Bielack S; Lamprecht-Dinnesen A; Frey E; Beck JD;
    Cancer Invest; 2005; 23(3):201-7. PubMed ID: 15945505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Otoacoustic emissions and tinnitus.
    Wilson JP
    Scand Audiol Suppl; 1986; 25():109-19. PubMed ID: 3472315
    [No Abstract]   [Full Text] [Related]  

  • 40. Neurochemistry of the peripheral and central auditory system after ototoxic drug exposure: implications for tinnitus.
    Rybak LP
    Int Tinnitus J; 2005; 11(1):23-30. PubMed ID: 16419684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.